Assault On Drug Marketing Tactics Becomes Drug-Specific On Capitol Hill
Executive Summary
Pharmaceutical firms avoided a moratorium on direct-to-consumer television ads in the FDA Amendments Act, but that victory seems of little comfort now as Congress undertakes a wide-ranging probe of industry marketing practices
You may also be interested in...
Academic Detailing Bill Could Be Interim Step To Comparative Effectiveness
Congressional critics of pharmaceutical marketing practices launched another volley in their battle to curb industry influence on prescribers with the July 31 introduction of legislation that would create a federally-supported "academic detailing" program
Academic Detailing Bill Could Be Interim Step To Comparative Effectiveness
Congressional critics of pharmaceutical marketing practices launched another volley in their battle to curb industry influence on prescribers with the July 31 introduction of legislation that would create a federally-supported "academic detailing" program
Will Schering-Plough’s Vytorin Headache Prove Contagious?
The full impact of Schering-Plough's deepening woes after a scientific panel's negative analysis of the Vytorin ENHANCE trial will not be known for a while, and some analysts predict there could be repercussions beyond the company and its joint venture with Merck, a deal centered on the anti-cholesterol drug, which combines the statin Zocor (simvastatin) withZetia (ezetimibe)